Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational ...
EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic ...
Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy. The inclusion of Dr. Thomas B.
HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc. (TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback